Alex Gariti
Dados Biográficos
| ID | 9596267 |
|---|---|
| NOME | Alex Gariti |
| PRENOMES | Alex |
| SOBRENOME | Gariti |
| ASSINATURA | GARITI A |
| AFILIAÇÕES | Baylor College of Medicine |
| ORCID | 0000-0002-0655-2055 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAÇÕES | 0 |
| OBRAS COMO AUTOR | 2 |
| OBRAS COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2026 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2026 |
| ÍNDICE H | 0 |
Slide the scale back
Decision-making capacity (DMC) assessments determine whether patients may authorize medical interventions, yet the prevailing sliding-scale model, requiring greater certainty of capacity for higher-risk decisions, fails to account for the ethical implications of declaring a patient incapacitated. When patients are found to lack DMC, decision-making authority shifts to surrogate decision-makers, whose well-documented inaccuracy in predicting patie…
Harm reduction in paediatric off-label therapy
Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and…
Sem obras proeminentes nesta página.
Slide the scale back
Decision-making capacity (DMC) assessments determine whether patients may authorize medical interventions, yet the prevailing sliding-scale model, requiring greater certainty of capacity for higher-risk decisions, fails to account for the ethical implications of declaring a patient incapacitated. When patients are found to lack DMC, decision-making authority shifts to surrogate decision-makers, whose well-documented inaccuracy in predicting patie…
Harm reduction in paediatric off-label therapy
Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and…
Best interests (1 obra) · Certainty (1 obra) · Clinical Ethics (1 obra) · Clinical judgment (1 obra) · Cystic fibrosis (1 obra) · Cystic Fibrosis Research Advances (1 obra) · Cystic fibrosis transmembrane conductance regulator (1 obra) · Disease (1 obra) · Do no harm (1 obra) · Ethics and Legal Issues in Pediatric Healthcare (1 obra)